サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784094

RNA療法の臨床試験の世界市場

RNA Therapy Clinical Trials

出版日
ページ情報
英文 244 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
RNA療法の臨床試験の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 244 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

RNA療法の臨床試験の世界市場は2030年までに36億米ドルに達する

2024年に30億米ドルと推定されるRNA療法の臨床試験の世界市場は、2024～2030年の分析期間においてCAGR 3.2%で成長し、2030年には36億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるRNA干渉は、CAGR 2.6％を記録し、分析期間終了までに17億米ドルに達すると予想されます。アンチセンス療法分野の成長率は、分析期間でCAGR 4.2％と推定されます。

米国市場は7億8,340万米ドルと推定、中国はCAGR 3.2％で成長すると予測

米国のRNA療法の臨床試験市場は、2024年に7億8,340万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを3.2%として、2030年までに5億8,370万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と2.9%と予測されています。欧州では、ドイツがCAGR 2.7%で成長すると予測されています。

世界のRNA療法の臨床試験市場- 主要動向と促進要因のまとめ

なぜRNAベース療法が臨床研究で注目を集めているのか？

RNAベースの治療薬は、複数の疾患領域において治療パラダイムを変革する可能性があることから、臨床試験の場で急速に注目を集めています。従来の低分子医薬品とは異なり、RNA療法は非常に特異的な作用機序を持ち、正確な遺伝子調節、タンパク質の置換、免疫調節を可能にします。COVID-19パンデミックにおけるmRNAワクチンの成功は、RNAベースのプラットフォームが、迅速で、スケーラブルで、非常に効果的な治療薬の開発において計り知れない可能性を秘めていることを実証しました。ワクチン以外にも、RNA干渉（RNAi）、アンチセンスオリゴヌクレオチド（ASO）、メッセンジャーRNA（mRNA）ベースの薬剤が、希少な遺伝性疾患からがんや神経変性疾患まで、幅広い疾患に対して研究されています。さらに、RNA治療の設計は柔軟であるため、迅速な変更や個別化治療アプローチが可能であり、精密医療において特に魅力的です。これらの要因により、RNAベースの医薬品を評価する臨床試験が急増し、製薬会社や研究機関はRNA治療薬の上市に向けた取り組みを強化しています。

RNA送達システムの進歩は、臨床試験の成功をどのように高めているのか？

RNA治療薬開発における最も重要な課題の一つは、効率的で的を絞ったデリバリーです。脂質ナノ粒子（LNP）、ポリマーベースのキャリア、細胞外小胞を介したデリバリーにおける最近の進歩は、RNA薬剤の安定性、バイオアベイラビリティ、細胞内取り込みにおけるこれまでの障壁を克服しつつあります。特にLNP技術は、COVID-19 mRNAワクチンの成功に重要な役割を果たし、現在では腫瘍学や希少疾患治療など、より広範な用途に最適化されつつあります。さらに、GalNAc（N-アセチルガラクトサミン）結合siRNAのような結合戦略は、肝臓標的RNAドラッグデリバリーを改善し、潜在的な治療範囲を広げています。これらの技術革新は臨床試験の成果を高め、毒性を低減し、RNAベースの治療に対する患者の反応を改善しています。デリバリー・プラットフォームの継続的な改良は、RNA療法の臨床試験の重要な実現要素であり、次世代RNAベース治療薬の開発スケジュールを加速します。

RNA臨床試験に影響を与える主な規制・投資動向は？

RNAベースの治療薬に対する規制状況は進化しており、FDAやEMAなどの機関は有望なRNA医薬品に迅速な承認経路を提供しています。特に希少疾患や腫瘍の分野では、RNAベースの治療薬に画期的治療薬や希少疾病用医薬品の指定が与えられることが増えています。一方、ベンチャーキャピタルからの資金流入と官民連携が臨床試験の拡大を後押ししており、大手バイオテクノロジー企業は学術研究センターと連携してRNA医薬品の開発を急ピッチで進めています。さらに、バイオマーカー主導型臨床試験デザインの進歩により、より効率的な患者層別化が可能となり、試験の成功率が高まっています。規制当局がRNA療法の増加の波に適応するにつれ、業界では複数の適応症で新たな臨床試験の開始が急増し、市場の成長をさらに後押ししています。

RNA療法の臨床試験市場の急成長の原動力は？

RNA療法の臨床試験市場の成長は、RNAベースのワクチンの成功、RNA医薬品開発への投資の増加、RNAデリバリー技術の進歩など、いくつかの要因によって牽引されています。遺伝性疾患、神経変性疾患、がんの有病率の上昇は、革新的なRNAベースの介入に対する需要を加速させています。AIを活用した臨床試験プラットフォームの拡大は、RNA合成・修飾技術の向上と相まって、医薬品開発プロセスをさらに合理化しています。個別化医療の推進もRNA治療への関心を高めており、そのモジュール設計は個別化治療アプローチへの迅速な適応を可能にしています。さらに、有利な規制政策や、ヘルスケアプロバイダーや患者の間でRNAベースの治療法が受け入れられつつあることで、強固な臨床試験エコシステムが構築されつつあります。RNA医薬品の治療可能性が検証されつつある現在、強力な科学的革新、規制当局の支援、業界連携の強化に支えられ、市場は継続的に拡大するものと思われます。

セグメント

モダリティ（RNA干渉、アンチセンス療法、メッセンジャーRNA、その他）;臨床試験フェーズ（フェーズi、フェーズII、フェーズIII、フェーズIV）;治療領域（希少疾患、抗感染症、抗がん、神経、消化器／代謝、筋骨格系、心血管系呼吸器、感覚器、その他）

調査対象企業の例

  • Abivax
  • Alnylam Pharmaceuticals
  • Arcturus Therapeutics
  • Aro Biotherapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • Avidity Biosciences
  • Biogen Inc.
  • BioNTech SE
  • Capricor Therapeutics
  • Cartesian Therapeutics
  • CureVac AG
  • Dicerna Pharmaceuticals
  • eTheRNA immunotherapies
  • Ethris GmbH
  • GSK（GlaxoSmithKline）
  • Ionis Pharmaceuticals
  • Lexeo Therapeutics
  • Moderna Inc.
  • Nutcracker Therapeutics

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32836

Global RNA Therapy Clinical Trials Market to Reach US$3.6 Billion by 2030

The global market for RNA Therapy Clinical Trials estimated at US$3.0 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. RNA interference, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Antisense therapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$783.4 Million While China is Forecast to Grow at 3.2% CAGR

The RNA Therapy Clinical Trials market in the U.S. is estimated at US$783.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$583.7 Million by the year 2030 trailing a CAGR of 3.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global RNA Therapy Clinical Trials Market - Key Trends & Drivers Summarized

Why Are RNA-Based Therapies Gaining Traction In Clinical Research?

RNA-based therapies are rapidly gaining prominence in the clinical trial landscape, driven by their potential to revolutionize treatment paradigms across multiple disease areas. Unlike traditional small-molecule drugs, RNA therapies offer highly specific mechanisms of action, enabling precise gene regulation, protein replacement, and immune modulation. The success of mRNA vaccines during the COVID-19 pandemic has demonstrated the immense potential of RNA-based platforms in developing rapid, scalable, and highly effective therapeutics. Beyond vaccines, RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA)-based drugs are being explored for conditions ranging from rare genetic disorders to cancer and neurodegenerative diseases. Additionally, the flexibility of RNA therapy design allows for rapid modifications and personalized treatment approaches, making them particularly attractive in precision medicine. These factors have propelled a surge in clinical trials evaluating RNA-based drugs, with pharmaceutical companies and research institutions intensifying their efforts to bring RNA therapeutics to market.

How Are Advances In RNA Delivery Systems Enhancing Clinical Trial Success?

One of the most significant challenges in RNA therapy development has been efficient and targeted delivery. Recent advancements in lipid nanoparticles (LNPs), polymer-based carriers, and extracellular vesicle-mediated delivery are overcoming previous barriers to RNA drug stability, bioavailability, and cellular uptake. LNP technology, in particular, played a critical role in the success of COVID-19 mRNA vaccines and is now being optimized for broader applications, including oncology and rare disease therapies. Additionally, conjugation strategies, such as GalNAc (N-acetylgalactosamine)-conjugated siRNAs, are improving liver-targeted RNA drug delivery, expanding their potential therapeutic scope. These innovations are enhancing clinical trial outcomes, reducing toxicity, and improving patient responses to RNA-based treatments. The continuous refinement of delivery platforms is a key enabler of RNA therapy clinical trials, accelerating the development timeline for next-generation RNA-based therapeutics.

What Are The Key Regulatory & Investment Trends Influencing RNA Clinical Trials?

The regulatory landscape for RNA-based therapeutics is evolving, with agencies such as the FDA and EMA providing accelerated approval pathways for promising RNA drugs. Breakthrough therapy designations and orphan drug status are increasingly being granted to RNA-based treatments, particularly in the fields of rare diseases and oncology. Meanwhile, the influx of venture capital funding and public-private partnerships is driving clinical trial expansion, with major biotech firms collaborating with academic research centers to fast-track RNA drug development. Additionally, advancements in biomarker-driven clinical trial designs are enabling more efficient patient stratification, enhancing trial success rates. As regulatory agencies adapt to the growing wave of RNA therapies, the industry is witnessing a surge in new trial initiations across multiple indications, further fueling market growth.

What Is Driving The Rapid Growth Of The RNA Therapy Clinical Trials Market?

The growth in the RNA therapy clinical trials market is driven by several factors, including the success of RNA-based vaccines, increasing investment in RNA drug development, and advancements in RNA delivery technologies. The rising prevalence of genetic disorders, neurodegenerative diseases, and cancer is accelerating the demand for innovative RNA-based interventions. The expansion of AI-powered clinical trial platforms, coupled with improvements in RNA synthesis and modification techniques, is further streamlining the drug development process. The push toward personalized medicine is also driving interest in RNA therapies, as their modular design enables rapid adaptation for individualized treatment approaches. Additionally, favorable regulatory policies and the growing acceptance of RNA-based therapies among healthcare providers and patients are creating a robust clinical trial ecosystem. As research continues to validate the therapeutic potential of RNA drugs, the market is set for continued expansion, backed by strong scientific innovation, regulatory support, and increasing industry collaboration.

SCOPE OF STUDY:

The report analyzes the RNA Therapy Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (RNA interference, Antisense therapy, Messenger RNA, Others); Clinical Trials Phase (Phase I, Phase II, Phase III, Phase IV); Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • Abivax
  • Alnylam Pharmaceuticals
  • Arcturus Therapeutics
  • Aro Biotherapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • Avidity Biosciences
  • Biogen Inc.
  • BioNTech SE
  • Capricor Therapeutics
  • Cartesian Therapeutics
  • CureVac AG
  • Dicerna Pharmaceuticals
  • eTheRNA immunotherapies
  • Ethris GmbH
  • GSK (GlaxoSmithKline)
  • Ionis Pharmaceuticals
  • Lexeo Therapeutics
  • Moderna Inc.
  • Nutcracker Therapeutics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • RNA Therapy Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neurological Diseases Spurs Demand for RNA Therapy Clinical Trials in Central Nervous System Disorders
    • Increasing Role of Personalized Medicine in RNA Therapeutics Expands Addressable Market for RNA-Based Clinical Trials
    • Regulatory Advancements in RNA Therapy Approvals Strengthen the Pathway for Clinical Trials and Accelerate Product Development
    • Growth in RNA Vaccine Research and Applications Drives Demand for RNA Therapy Clinical Trials Post-COVID-19
    • Surge in Academic and Industry Collaboration Drives RNA Therapy Innovation and Clinical Trial Advancements
    • Enhanced Focus on Rare and Undruggable Diseases Creates Opportunities for RNA Therapeutics in Clinical Trials
    • Technological Advancements in mRNA Delivery Systems Propel Growth in RNA Therapy Clinical Trials
    • Integration of AI and Machine Learning in RNA Drug Discovery Expands Clinical Trial Opportunities and Accelerates Development
    • Increasing Consumer and Patient Advocacy for Advanced Therapeutics Drives Interest in RNA Therapy Clinical Trials
    • Expanding Global Healthcare Infrastructure and Clinical Trial Networks Create New Growth Opportunities for RNA Therapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World RNA Therapy Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for RNA Therapy Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for RNA Therapy Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for RNA interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for RNA interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for RNA interference by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antisense therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antisense therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Antisense therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Messenger RNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Messenger RNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Messenger RNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Anti-infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Anti-infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Anti-infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Anticancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Anticancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Anticancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Neurological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Neurological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Neurological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Alimentary / Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Alimentary / Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Alimentary / Metabolic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Musculoskeletal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Musculoskeletal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Musculoskeletal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cardiovascular Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Cardiovascular Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Cardiovascular Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Sensory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Sensory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Sensory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • JAPAN
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • CHINA
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • EUROPE
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for RNA Therapy Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • FRANCE
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • GERMANY
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of World Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of World 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of World Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of World 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of World Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of World 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030

IV. COMPETITION